News coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has trended positive recently, according to AlphaOne Sentiment Analysis. The research firm, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a daily sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave news headlines about the specialty pharmaceutical company an impact score of 86 out of 100, meaning that recent media coverage is very likely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted AlphaOne Sentiment Analysis’s scoring:
- AMAG Pharmaceuticals Down 29.1% Since SmarTrend Downtrend Call (AMAG) (mysmartrend.com)
- AMAG Pharmaceuticals, Inc.’s (AMAG) registers a price change of 3.08% while Heron Therapeutics, Inc.’s (HRTX … – Stocks Gallery (stocksgallery.com)
- AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs – Nasdaq (nasdaq.com)
Several equities research analysts have recently weighed in on AMAG shares. JPMorgan Chase & Co. set a $24.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, January 31st. Jefferies Group LLC set a $40.00 price target on AMAG Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, April 20th. Cantor Fitzgerald set a $24.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, February 27th. Guggenheim cut their target price on AMAG Pharmaceuticals from $42.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, February 2nd. Finally, Cowen and Company lowered AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 3rd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals has an average rating of “Hold” and a consensus target price of $30.00.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 1.82% on Friday, reaching $18.90. The company’s stock had a trading volume of 597,093 shares. AMAG Pharmaceuticals has a 12-month low of $17.90 and a 12-month high of $36.83. The company’s 50 day moving average price is $21.79 and its 200 day moving average price is $26.00. The company’s market cap is $662.35 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. The business had revenue of $139.47 million during the quarter, compared to the consensus estimate of $150.32 million. During the same period in the previous year, the business posted ($0.22) EPS. The firm’s revenue was up 27.6% on a year-over-year basis. Analysts forecast that AMAG Pharmaceuticals will post $5.13 EPS for the current fiscal year.
In related news, SVP Julie Krop sold 1,891 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the completion of the transaction, the senior vice president now owns 36,777 shares of the company’s stock, valued at approximately $899,197.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.30% of the stock is currently owned by company insiders.
WARNING: This news story was first reported by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/amag-pharmaceuticals-amag-earns-daily-coverage-optimism-score-of-0-31-updated-updated-updated/629404.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.